<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this work was to study clinical and histopathological <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics of patients treated for synchronous or metachronous skeletal <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> at The Norwegian <z:chebi fb="16" ids="33325">Radium</z:chebi> Hospital from January 1, 1980 to January 1, 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>Patients and methods </plain></SENT>
<SENT sid="3" pm="."><plain>The hospital <z:hpo ids='HP_0100242'>sarcoma</z:hpo> database and patient records were reviewed to identify cases with synchronous or metachronous skeletal <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with more than one skeletal lesion in the absence of pulmonary or other <z:mpath ids='MPATH_404'>soft tissue tumor</z:mpath> manifestations were included in the study, and histopathological slides from these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>Results </plain></SENT>
<SENT sid="6" pm="."><plain>Among a total of 297 registered <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> patients, six with synchronous (2.0%) and 10 with metachronous (3.4%) skeletal <z:hpo ids='HP_0002669'>osteosarcomas</z:hpo> were identified </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were of high-grade <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment at the time of the first <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> diagnosis was in most cases wide resections and multi-agent chemotherapy according to international protocols, whereas the treatment for metachronous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was individualized and in general much less intensive </plain></SENT>
<SENT sid="9" pm="."><plain>One patient was diagnosed with <z:e sem="disease" ids="C0085390" disease_type="Neoplastic Process" abbrv="LFS">Li-Fraumeni syndrome</z:e>, two other individuals may be suspected to have the same syndrome, and yet another patient had previously been treated for a bilateral <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Thirteen patients are dead, 11 from metastatic <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo>, one from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and one from wound <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi>-related nephrotoxicity; whereas three patients are still alive with no evidence of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Conclusions </plain></SENT>
<SENT sid="12" pm="."><plain>The prognosis for patients with synchronous and metachronous skeletal <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> is poor </plain></SENT>
<SENT sid="13" pm="."><plain>However, because long-term survival is seen, aggressive treatment to selected cases, e.g., patients with an <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> predisposing syndrome and/or late occurring metachronous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, is justified </plain></SENT>
<SENT sid="14" pm="."><plain>Revealing a possible clonal relationship between these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, e.g., by karyotyping, may be of interest for estimating prognosis and guide therapy intensiveness </plain></SENT>
</text></document>